Covid-19 roundup: Pfiz­er, BioN­Tech kick off EUA dance for teen bi­va­lent shot; Re­port de­tails slow US boost­er roll­out

While Mod­er­na’s vac­cine has been sent off for an EUA for teens and pre­teens, its ri­vals, Pfiz­er and BioN­Tech, are right on its heels with an EUA sub­mis­sion of their own.

On Mon­day, both com­pa­nies an­nounced that they fin­ished sub­mit­ting an EUA to the FDA for the bi­va­lent boost­er for chil­dren aged five through 11 to counter the Omi­cron BA.4/BA.5 strains of Covid-19. Both com­pa­nies have al­so start­ed a “Phase I/II/III study” to eval­u­ate the safe­ty and tol­er­a­bil­i­ty of dif­fer­ent dos­ing reg­i­mens for the boost­er in chil­dren from six months to 11 years old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER